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Abstract
Background
Hand, foot and mouth disease (HFMD) is a common illness in China that mainly affects
infants and children. The objective of this study is to assess the economic cost and health-
related quality of life associated with HFMD in China.
Method
A telephone survey of caregivers were conducted in 31 provinces across China. Caregivers
of laboratory-confirmed HFMD patients who were registered in the national HFMD
enhanced surveillance database during 2012–2013 were invited to participate in the survey.
Total costs included direct medical costs (outpatient care, inpatient care and self-medica-
tion), direct non-medical costs (transportation, nutrition, accommodation and nursery), and
indirect costs for lost income associated with caregiving. Health utility weights elicited using
EuroQol EQ-5D-3L and EQ-Visual Analogue Scale (VAS) were used to calculate associated
loss in quality adjusted life years (QALYs).
Results
The subjects comprised 1136 mild outpatients, 1124 mild inpatients, 1170 severe cases and
61 fatal cases. The mean total costs for mild outpatients, mild inpatients, severe cases and
fatal cases were $201 (95%CI $187, $215), $1072 (95%CI $999, $1144), $3051 (95%CI
$2905, $3197) and $2819 (95%CI $2068, $3571) respectively. The mean QALY losses per
HFMD episode for mild outpatients, mild inpatients and severe cases were 3.6 (95%CI 3.4,
3,9), 6.9 (95%CI 6.4, 7.4) and 13.7 (95%CI 12.9, 14.5) per 1000 persons. Cases who were
diagnosed with EV-A71 infection and had longer duration of illness were associated with
higher total cost and QALY loss.
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Conclusion
HFMD poses a high economic and health burden in China. Our results provide economic
and health utility data for cost-effectiveness analysis for HFMD vaccination in China.
1. Introduction
Hand, foot and mouth disease (HFMD) is an acute communicable disease caused by enterovi-
ruses, most commonly enterovirus A71 (EV-A71) and coxsackie virus A16 (CV-A16). [1]
Most HFMD cases are children under five years of age, with those younger than three years of
age being the most susceptible.[2–3] HFMD has been the leading cause of morbidity among all
nationally notifiable diseases since 2009 and become a major public health concern which is
associated with a substantial burden of disease in China. [4–5]
EV-A71 vaccines are the first vaccines developed against HFMD and became commercially
available in China in 2016 [6]. Although EV-A71 vaccination may be the most effective way
for alleviating the disease burden of HFMD, their inclusion into the national immunization
program depends on their cost-effectiveness. A key input for cost-effectiveness analysis is the
economic costs and the effect on health-related quality of life (HRQoL) associated with
HFMD. However, most of the relevant cost data in the current literature are only available for
high-income provinces such as Shanghai and Jiangsu [7, 8]. Few studies have been conducted
in less developed provinces with higher HFMD incidence, such as Hunan and Guangxi. [9]
Regarding HRQoL of HFMD patients, there has only been one relevant study in a rural village
in Jiangsu. [8] The cost and HRQoL of HFMD patients in developed provinces are unlikely to
be representative of those in less developed regions. To address this knowledge gap, we con-
ducted a national telephone survey among caregivers of laboratory-confirmed HFMD cases
who were registered in the national HFMD enhanced surveillance database to estimate the
direct costs, indirect costs and quality-adjusted life years (QALY) lost associated with HFMD.
2. Methods
2.1 National HFMD enhanced surveillance database
The national HFMD enhanced surveillance database was established in 2008 to monitor the
spatial, temporal and population distribution of HFMD cases as well as serotype trends and
clinical severity of HFMD across mainland China. All medical institutions are required to
report clinically confirmed HFMD cases, including both mild and severe cases. Mild cases are
defined as patients with mouth vesicles and skin rashes on the hands and feet, fever, but no
complications; severe cases are defined as patients with neurological, respiratory, or circulation
complications besides the clinical manifestations of mild cases [10]. In each county/district,
specimens (stool, rectal or throat swabs) of the first five clinically confirmed mild HFMD cases
in each week and of all severe and fatal cases are collected and sent to local Centers for Disease
Control and Prevention (CDCs) for pathogen testing using real-time fluorescence relative
quantitative reverse transcription polymerase chain reaction (rRT-PCR). Demographics (e.g.,
age, gender), clinical details (e.g., date of symptoms onset, date of diagnosis, severity, and date
of death), and contact information (e.g., telephone number) of each clinically confirmed case
are recorded in the national HFMD enhanced surveillance database. For cases that are labora-
tory confirmed to be positive for enteroviruses, their serotyping results (i.e., EV-A71, CV-A16
or other enteroviruses (OEVs)) are also available.
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2.2 Participants
HFMD cases reported in the national HFMD enhanced surveillance database during 2012–
2013 were eligible for our study if they met the following inclusion criteria: (i) aged six months
to five years; (ii) laboratory confirmed HFMD cases; (iii) without other underlying diseases.
Previous studies suggest that the costs of HFMD varied significantly by level of severity. [7,
11–12] Consequently, participants in our study were stratified into four groups of severity:
mild cases who were outpatients (mild outpatients), mild cases who were hospitalized (mild
inpatients), severe cases and fatal cases.
A total of 192,859 laboratory-confirmed HFMD cases were reported in the National surveil-
lance system in 2012–2013. Among those, 173,911 were aged between six months and five
years. Due to budget constraint, we aimed to enroll approximately 3,500 HFMD cases, which
corresponded to around 2.0% of all laboratory-confirmed HFMD cases in 2012–2013. We
reached our target sample size after contacting 29,810 laboratory-confirmed cases. Among
these 3,500 subjects, 1136, 1124 and 1170 were mild outpatients, mild inpatients and severe
cases, respectively. The expected standard error was 23.2 Chinese Yuan (CNY), 71.1 CNY and
125.3 CNY for economic costs of mild outpatients, mild inpatients and severe cases. [11] Since
the total number of fatal cases was limited, all eligible cases were included in our survey. Our
sampling scheme aimed to recruit equal number of participants from each of the seven regions
of China. If there were insufficient candidates in a given region, then we recruited from its
neighboring regions in order to reach our target sample sizes. The distribution of age, gender
and aetiology (EV-A71, CV-A16 and OEV) of participants recruited in each severity stratum
(except fatal cases) matched with that reported in the national HFMD enhanced surveillance
database in 2013.
2.3 Telephone survey
Telephone surveys were conducted between 1 Dec 2013 and 15 Jan 2014 among caregivers of
HMFD patients. Each telephone number was dialed up to five times on different days before
being classified as unreachable. After explaining the study and obtaining verbal consent, we
verified both the demographic and clinical details of each patient. Then the interviewees were
encouraged to recall information about costs and HRQoL related to that HFMD episode. The
questionnaire contained questions about: 1) disease information (e.g., complications, duration
of illness); 2) treatment (e.g., number of outpatient visits, duration of hospitalization); 3) costs
associated with the first four outpatient visits and first two hospitalizations (e.g., costs of pre-
scribed medications and examinations, transportation, food, accommodation, nutrition and
snacks, nursery, number of caregivers and days-off-work) and self-medication (S1 Table).
Interviewees were asked to recall total medical costs, which were specified on their medical
bills (including both out-of-pocket expenses and payments by insurers). If the interviewees
could not recall the costs, they were asked to select from a list of cost ranges (S1 Table). The
lower limit of the selected range was used in the base-case analyses, while the upper limit of the
range was used in the sensitivity analyses.
Alongside the aforementioned economic cost survey, EuroQoL EQ-5D-3L (hereafter “EQ-
5D”) instruments were used to solicit the HRQoL of patients during their HFMD episode.
HRQoL is defined as those aspects of self-perceived well-being that are related to or affected by
the presence of disease or treatment. [13] As an important parameter in cost-effectiveness
analysis, HRQol for HFMD patients measures the effect of disease on health states.
The EQ-5D is a widely used generic instrument for measuring non-disease-specific
HRQoL, comprising a descriptive system (with five dimensions: mobility, self-care, usual
activity, pain/discomfort, and anxiety/depression) and a visual analogue scale (VAS) (i.e., a
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scale from 0 to 100, with the extreme values representing death and full health, respectively).
Subjects in this study were children aged between six months and five years. As such, the
slightly altered proxy version (proxy 2, in which proxies (parents or caregivers) are asked to
rate how they think their children would rate their HRQoL) (S1 Table) in simplified Chinese
was used in this survey. The mobility dimension was not scored for patients younger than 18
months because not all children at these ages were able to move independently. The self-care
dimension was not scored for all patients because most children under the age of five were
unlikely to care for themselves. For those participants, the mobility and self-care dimensions
both were given the value of “no problems” in the baseline analysis and “severe problems” in
the sensitivity analysis.
To assess the reliability of caregiver-reported costs compared to costs from medical
accounts, we conducted a review of medical accounts of 15 severe HMFD patients reported in
Xi’an Children hospital, a designated tertiary hospital for HFMD treatment in Northwest
China.
2.4 Data analysis
The economic cost of an HFMD episode was calculated as the sum of direct medical costs (pre-
scription and over-the-counter medicines, outpatient and inpatient treatment), direct non-
medical costs (transportation, accommodation, food, nutrition, snacks and nursery care) and
indirect costs (productivity loss of caregivers due to lost workdays). Indirect costs were calcu-
lated using the human capital method, by multiplying mean daily income per capita with the
days off work taken by caregiving parents. [14] Indirect costs due to premature deaths were
not considered.
Responses to the EQ-5D descriptive system were converted into health utilities using a
China-specific value set. Several such sets have been developed; we used the set estimated
using ordinary least squares regression fitted to time trade-offs for respondents presented with
different health states (the “N3 model” in [15]). QALY loss was then estimated by multiplying
the difference in health utility between the HFMD episode and full health (assuming the health
utility equals to one) with the reported duration of HFMD illness (S1 File). We expressed the
results as QALY loss per 1000 cases (QALY loss multiple 1000) instead of QALY loss per case
because the magnitude of the latter was small.
The crude mean cost and HRQoL estimates among our subjects were not representative
because the geographical distribution of HFMD cases in the national database was different
from that of our subjects. As such, we weighted the region-specific cost and QALY loss esti-
mates by the number of cases in each geographic region as reported in the national HFMD
enhanced surveillance database (S2 Table). Detailed equations are shown in S1 File.
Statistical analyses were performed using STATA 12.0 (StataCorp, Texas, USA). Costs in
2012 were inflated to 2013 values using the medical consumer price index for China (1.03)
[16] and presented in US dollar using an exchange rate at 6.2 [17]. Bootstrap multiple linear
regression (1,000 replications) was used to analyze the determinants of the total cost. Although
the distribution of QALY loss was left-skewed, the sample size was large. Thus, we used t-test
and ANOVA to analyze the differences in QALY losses between groups. The significance level
was set at 0.05.
2.5 Ethical approval and informed consent
During the interview, the interviewers explained the objective and other details of the study
before starting the interview. Once the interviewees agreed to participant the interview, the
interviewers started the survey. All of interviews were conducted by telephone, hence we used
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the verbal consents instead the written ones. All verbal informed consents and the telephone
survey dialogues were documented in CDs. All the study protocol were submitted to and
reviewed by the institutional review board of China CDC and the ethical approval (Approval
number: 201417) was acquired.
3. Results
3.1 Sample selection
We contacted 29,810 eligible HFMD cases by phone. Among these 29,810 candidates, 9937
cases were unreachable because their phone number were invalid, their lines were shutdown,
or our calls were unanswered. We interviewed 3,500 cases after establishing contact with
19,873 candidates, i.e. a response rate of 17.6% (3,500/19,873). Reasons for non-participation
(n = 16373) included busy line or not answering (n = 6455), unwillingness to be interviewed
(n = 4953), identity mismatch (n = 2658), language barriers (n = 324), wrong number
(n = 154), and unknown (n = 1829). Nine fatal cases were excluded because the national data-
base did not have their aetiologic details. The subjects for our main analysis comprised 3,491
laboratory confirmed HFMD cases. (Fig 1).
3.2 Demographic and clinical information
The demographic and clinical information of HFMD patients in the telephone survey are
show in Table 1. Most of the 3491 HFMD cases were male (66%), under three years of age
(68%), and diagnosed with EV-A71 (51%). The duration of illness for severe HFMD patients
(12.0 days, SD 7.1 days) were longer than that of mild outpatients (7.1 days, SD 4.0 days), mild
inpatients (8.8 days, SD 4.5 days), and fatal cases (7.8 days, SD 5.6 days). (S1 Fig)
3.3 Self-reported economic cost
Recalled self-reported costs associated with HFMD illness are shown in Fig 2. The total costs
for mild outpatients, mild inpatients, severe cases and fatal cases (after weighting by geo-
graphic distribution of cases) were $196 (95%CI $75, $318), $990 (95%CI $431, $1549), $3084
(95%CI $813, $5354) and $2348 (95%CI $1006, $3689) respectively. Direct medical costs
accounted for 44%, 71%, 82% and 76% of the total costs for mild outpatient, mild inpatients,
severe cases and fatal cases. Multiple linear regression showed that costs were higher in
patients who had longer duration of illness, were diagnosed with EV-A71 infection, and were
three years old or younger. (S3 Table)
The cost estimates from our medical accounts review survey were 22.7% (95% CI 9.9% to
35.6%) higher than that in our telephone survey (see S4 Table for details).
3.4 Health-related quality of life
Table 2 summarizes the results of the HRQoL survey. Weighted QALY losses for mild outpa-
tients, mild inpatients and severe cases using the EQ-5D-3L were 3.5 (95%CI 3.4, 3.9), 6.9
(95%CI 6.4, 7.4) and 13.7 (95%CI 12.9, 14.5) per 1000 cases respectively. Mild inpatients and
outpatients under the age of three had higher QALY loss compared to their older counterparts
even if “no problem” was assigned to the “mobility” dimension for those younger than 18
months. (P<0.01) Mild inpatients and severe patients with EV-A71 infection had higher
QALY loss. (P<0.001) (S5 Table, S2 and S3 Figs). Among our subjects, HFMD had relatively
greater impact on their levels of anxiety/depression and pain/discomfort compared to their
mobility and usual activity.
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3.5 Sensitivity analysis
Among our subjects, caregivers of 33%, 49%, 48% and 30% of mild outpatients, mild inpa-
tients, severe cases and fatal cases were unable to recall the exact costs for at least one item. As
such, they were asked to choose from a list of cost ranges that we provided. When the upper-
limits of the cost ranges were used in our analyses, the total costs for mild outpatients, mild
inpatients, severe cases and fatal cases increased by 96%, 17%, 9% and 10%, respectively.
Eighteen percent, 21% and 25% of mild outpatients, mild inpatients and severe patients
were younger than 18 months. In our baseline analysis, we assigned “no problem” to the
mobility dimension of these cases. QALY loss estimates from EQ-5D for mild outpatients,
mild inpatients and severe cases increased by 153% (9.1 vs. 3.6), 100% (13.8 vs. 6.9) and 69%
(23.1 vs. 13.7) per 1000 cases, respectively, if (i) “severe problem” was assigned to the mobility
Fig 1. Flowchart of sample selection trough telephone interview.
https://doi.org/10.1371/journal.pone.0184266.g001
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dimension of these cases and (ii) “severe problem” was assigned to the self-care dimension of
all subjects.
4. Discussion
This is the first national study in China for estimating the economic costs and HRQoL of
HFMD patients by conducting telephone surveys of more than 3,000 caregivers of patients
across the country. We found that the economic cost per HFMD case ranges from around
$200 for a mild outpatient case to over $3,000 for a severe case, with most costs being direct
medical costs. The economic burden of mild outpatients, mild inpatients, severe cases and
fatal cases corresponded to 2.8%, 15.2%, 43.1% and 39.8% of the GDP per capita of China in
2013 [18], respectively.
Several studies have examined the economic costs associated with HFMD in China, but
they were restricted to relatively developed provinces in east China such as Shanghai [7, 19],
Jiangsu [8, 20], Zhejiang [21, 22] and Shandong [23–24]. Our study is the first to assess the
economic cost and HRQoL of HFMD patients from all seven geographic regions across China,
including relatively underdeveloped provinces with higher incidence of HFMD (such as
Hunan and Guangxi). [9] It also gave the first national representative results of economic and
QALY loss on HFMD, which provided a nationwide picture of the economic burden and
QALY loss for HFMD cases with different age, gender, severity, aetiology, geographies and
duration of illness.
Table 1. Demographic and clinical information of study participants (N = 3491) (n, %).
Mild outpatient
N = 1136
Mild inpatient
N = 1124
Severe
N = 1170
Fatal
N = 61
Total
Gender
Male 737(65) 743(66) 777(66) 35(57) 2292(66)
Age group
3 years 727(63) 767(68) 873(75) 44(72) 2411(69)
>3 years 409(36) 357(32) 297(25) 17(28) 1080(31)
Geographic regions
Northeast 171(15) 180(16) 41(3) 13(21) 405(12)
Northwest 164(14) 140(13) 197(17) 3(5) 504 (14)
North 164(14) 241(21) 100(9) 2(3) 507 (15)
Central 162(14) 136(12) 225(19) 5(8) 528 (15)
Southwest 144(13) 130(12) 221(19) 13(21) 508 (15)
East 173(15) 153(14) 169(14) 10(16) 505 (14)
South 158(14) 144(13) 217(19) 15(25) 534 (15)
Aetiologic classification
EV-A71 451(40) 484(43) 798(68) 54(88) 1787(51)
CV-A16 191(17) 172(15) 46(4) 1(2) 410(12)
OEV 494(43) 468(42) 326(28) 6(10) 1294 (37)
Duration of illness/days
5 237(21) 55(5) 26(2) 24(39) 342(10)
6–10 688(61) 710(63) 431(37) 17(28) 1846(53)
11–15 138(12) 225(20) 384(33) 10(16) 757(22)
16–20 52(5) 99(9) 204(17) 6(10) 361(10)
21 21(2) 35(3) 125(11) 4(7) 185(5)
EV-A71: enterovirus A 71, CV-A16: coxsackievirus A 16. OEV: other enterovirus.
https://doi.org/10.1371/journal.pone.0184266.t001
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Our cost estimates are comparable to those in previous surveys (when inflated to 2013 fig-
ures). The costs of mild outpatients in our study were similar to those from the studies in
Changchun [25] ($252 vs. $260 for the Northeast region in our study) and Jinan [24] ($270 vs.
$251 for the East region in our study). For mild inpatients, our results were similar to those
reported in the Changchun [25] ($1023 vs $922) and Shanghai [19] ($1051 vs $933 for the East
Fig 2. Self-reported economic costs per episode for HFMD patients in China.
https://doi.org/10.1371/journal.pone.0184266.g002
Table 2. Health related quality of life for HFMD patients in China.
Mild outpatient
N = 1136
Mild inpatient
N = 1124
Severe
N = 1170
Mean(95%CI) Median(IQR) Mean(95%CI) Median(IQR) Mean(95%CI) Median(IQR)
Health utility elicited by EQ-5D 0.83(0.82,0.83) 0.78(0.78,1.00) 0.74(0.73,0.75) 0.78(0.64,0.87) 0.61(0.59,0.62) 0.62(0.44,0.78)
Health utility elicited by EQ-VAS 75(74,76) 80(60,90) 68(67,69) 70(50,80) 56(54,57) 60(0,100)
QALY loss per 1000 cases 3.6(3.4, 3.9) 2.7(0.2, 3.9) 6.9(6.4, 7.4) 4.8(2.5, 8.5) 13.7(12.9, 14.5) 9.6(0,77.3)
Weighted QALY loss per 1000 cases 3.5(1.7,5.2) 3.3(1.9,4.7) 6.4(3.6, 9.3) 6.2(3.0, 10.2) 13.7(3.9, 23.5) 9.3(4.3, 24.8)
% of problem reported in each dimension
Mobility# 7 18 44
Usual activity 18 33 54
Pain/discomfort 61 74 79
Anxiety/depression 62 74 87
#
“No problem” was given to “self-care” for all participants and to “mobility” for those who were younger than 18 months.
https://doi.org/10.1371/journal.pone.0184266.t002
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region in our study). For severe patients, the costs in this study were similar to those in the
Wuxi study [20] ($3546 vs $3,059 for the East region in our study).
In this study, we obtained the self-reported recall costs from telephone interview. Unlike
our study, most economic studies of illness conducted in developed countries used national
medical insurance database. However, a nationwide medical insurance dataset was not avail-
able in China. As such, self-reported costs from patients is the only practical source of nation-
ally representative data in China. Given that self-reported costs are subject to recall bias, we
conducted a small cost validation study alongside our survey to gauge the accuracy and repre-
sentativeness of our estimates.
The HRQoL for EV-A71 HFMD patients has only been reported in one study [8] which
suggested that disability adjusted life years (DALY) incurred by an HFMD episode was
1.76/1000 for mild patients and 3.47/1000 for severe patients. Our HRQoL results are not
directly comparable with theirs due to differences in methodology (e.g., in the design of sur-
vey instruments and utility measures) [26]. When compared with the health utility for chil-
dren who had similar diseases, such as acute rotavirus gastroenteritis with same elicitation
instrument, [27] mild and severe HFMD cases had higher utility score (0.83 and 0.61) than
pediatric patients with acute rotavirus gastroenteritis (primary care cases: 0.69–0.78, severe
cases 0.08–0.26). This suggested that HFMD had less impact on health than acute rotavirus
gastroenteritis.
This study has a few major limitations. First, we did not retrieve individual medical records
because China does not have a centralized electronic health records database. Instead, we
asked interviewees to recall treatment costs, which were inevitably subject to recall bias. To
investigate the likely magnitude of this bias, we compared the reported costs with medical rec-
ords from a hospital in Xi’an. Our cost estimates were 22.7% (95% CI, 9.9%–35.6%) higher
than that in the medical records. Second, because there are no instruments suitable for eliciting
quality of life in young children, we used the proxy EQ-5D to assess the health utility and
QALY loss.[28] We modified the adult version of the EQ-5D by fixing the responses to the
“self-care” and “mobility” dimensions which were not applicable to very young children.[29]
We gave these dimensions a rating of either “no problems” (which may underestimate HFMD
impact) in the baseline analysis or “severe problems” in the sensitivity analyses. The sensitivity
analysis results showed that the difference between the two extreme ratings had little influence
on the HRQoL results for HFMD patients except for mild outpatients. Third, we used perfect
health as the comparator when estimating QALY loss. In practice, the health status for the gen-
eral population would not be perfect, hence we might have overestimated the QALY loss to
some extent. Finally, our study only included cases recorded in the national HFMD surveil-
lance system and hence ignored patients who did not seek medical treatment. Consequently,
our cost and QALY loss estimates might be biased.
Despite these limitations, this study provides a comprehensive assessment of economic
costs and HRQoL for HFMD patients in China. The first EV-A71 vaccines were licensed in
December 2015 in China [6]. These EV-A71 vaccines are being considered for inclusion in the
National Immunization Program in China due to heavy disease burden of HFMD[30]. Several
studies have been conducted to support evidence-based decision making about the appropriate
use of these vaccines in China. These include epidemiological studies of HFMD [4], transmis-
sion dynamic models to understand the impact of EV-A71 vaccination [31] and cost-effective-
ness analysis of routine pediatric EV-A71 vaccination. [32] This study enriches the evidence
base by providing nationally representative estimates of the economic costs and HRQoL of
HFMD episodes of different severities which will serve as key inputs for future economic eval-
uation of HFMD vaccines in China.
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